{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:56:06Z","timestamp":1787601366147,"version":"build-2736575974"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10140021910002"],"award-info":[{"award-number":["10140021910002"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Chemoradiotherapy with cisplatin in a triweekly regimen of 100 mg\/m2 body surface area, is used to treat locally advanced head and neck squamous cell carcinoma (HNSCC) with curative intent. Cisplatin dose limiting toxicity (CDLT) occurs often and impedes obtaining the planned cumulative cisplatin dose. A cumulative cisplatin dose of 200 mg\/m2 or more is warranted for better survival and locoregional control. Patients with a low skeletal muscle mass (SMM) have a three-fold higher risk of developing CDLT than patients with a normal SMM. SMM can be assessed through measurements on routinely performed diagnostic head and neck CT- or MRI-scans. A weekly regimen of 40 mg\/m2 body surface area cisplatin is proposed as a less toxic schedule, which possibly decreases the risk of developing CDLT and enables reaching a higher cumulative cisplatin dose. The aim of this multicenter randomized clinical trial (NL76533.041.21, registered in the Netherlands Trial Register) is to identify whether a regimen of weekly cisplatin increases compliance to the planned chemotherapy scheme in HNSCC patients with low SMM. The primary outcome is the difference in compliance rate, defined as absence of CDLT, between low SMM patients receiving either the weekly or triweekly regimen. Secondary outcomes consist of toxicities, the cumulative cisplatin dose, time to recurrence, incidence of recurrence at two years of follow-up, location of recurrence, 2-year overall, disease free and disease specific survival, quality of life, patient\u2019s experiences, and cost-effectiveness.<\/jats:p>","DOI":"10.1371\/journal.pone.0294147","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T19:14:15Z","timestamp":1701112455000},"page":"e0294147","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7952-8734","authenticated-orcid":true,"given":"Anouk W. M. A.","family":"Schaeffers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lot A.","family":"Devriese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla H.","family":"van Gils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem","family":"Dankbaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-2614","authenticated-orcid":true,"given":"Jens","family":"Voortman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Paul","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathijs P.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst J.","family":"Smid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert W. J.","family":"Frederix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7128-5814","authenticated-orcid":true,"given":"Remco","family":"de Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"issue":"6","key":"pone.0294147.ref001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin."},{"issue":"4","key":"pone.0294147.ref002","doi-asserted-by":"crossref","first-page":"e2106","DOI":"10.1002\/rcs.2106","article-title":"Use of the transoral robotic surgery to treat patients with recurrent lingual tonsillitis","volume":"16","author":"M Di Luca","year":"2020","journal-title":"Int J Med Robot"},{"issue":"SUPPL. 5","key":"pone.0294147.ref003","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/annonc\/mdq185","article-title":"Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"21","author":"V Gr\u00e9goire","year":"2010","journal-title":"Ann Oncol."},{"issue":"1","key":"pone.0294147.ref004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"DJ Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"issue":"22","key":"pone.0294147.ref005","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"AA Forastiere","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0294147.ref006","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.prro.2017.02.002","article-title":"Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline","volume":"7","author":"DJ Sher","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"AUG","key":"pone.0294147.ref007","first-page":"1","article-title":"Best practice in systemic therapy for head and neck squamous cell carcinoma","volume":"9","author":"SF Oosting","year":"2019","journal-title":"Front Oncol"},{"issue":"11","key":"pone.0294147.ref008","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS\u2013ESMO\u2013ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020.","volume":"31","author":"JP Machiels","year":"2020","journal-title":"Ann Oncol."},{"issue":"1","key":"pone.0294147.ref009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: A randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer","volume":"39","author":"M Gebre-Medhin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0294147.ref010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients.","volume":"92","author":"JP Pignon","year":"2009","journal-title":"Radiother Oncol."},{"issue":"24","key":"pone.0294147.ref011","first-page":"2081","article-title":"Randomized Trial of Radiation Therapy Versus","volume":"91","author":"G Calais","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"9208","key":"pone.0294147.ref012","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(00)90011-4","article-title":"Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data","volume":"355","author":"JP Pignon","year":"2000","journal-title":"Lancet"},{"key":"pone.0294147.ref013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00086","article-title":"Low-dose vs. high-dose cisplatin: Lessons learned from 59 chemoradiotherapy trials in head and neck cancer","volume":"9","author":"P Szturz","year":"2019","journal-title":"Front Oncol"},{"key":"pone.0294147.ref014","author":"National Cancer Institute","year":"2017","journal-title":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events Version 5.0"},{"issue":"16","key":"pone.0294147.ref015","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.7314\/APJCP.2015.16.16.7331","article-title":"Concurrent chemoradiation with weekly cisplatin for the treatment of head and neck cancers: An institutional study on acute toxicity and response to treatment","volume":"16","author":"S Ghosh","year":"2015","journal-title":"Asian Pacific J Cancer Prev"},{"issue":"108","key":"pone.0294147.ref016","first-page":"57","article-title":"da Costa e Silva VT, de Castro G. Cisplatin based chemoradiation late toxicities in head and neck squamous cell carcinoma patients","volume":"20","author":"TG Rivelli","year":"2015","journal-title":"Discov Med"},{"key":"pone.0294147.ref017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.05.012","article-title":"Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer","volume":"71","author":"AW Wendrich","year":"2017","journal-title":"Oral Oncol"},{"key":"pone.0294147.ref018","article-title":"The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin","author":"SI Bril","year":"2021","journal-title":"Head Neck"},{"key":"pone.0294147.ref019","doi-asserted-by":"crossref","first-page":"105483","DOI":"10.1016\/j.oraloncology.2021.105483","article-title":"Impact of sarcopenia in locally advanced head and neck cancer treated with chemoradiation: An Indian tertiary care hospital experience.","volume":"121","author":"P Nagpal","year":"2021","journal-title":"Oral Oncol"},{"key":"pone.0294147.ref020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.oraloncology.2016.09.006","article-title":"Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients","volume":"62","author":"JE Swartz","year":"2016","journal-title":"Oral Oncol"},{"issue":"3","key":"pone.0294147.ref021","doi-asserted-by":"crossref","first-page":"317","DOI":"10.21053\/ceo.2018.01613","article-title":"Diagnosis of Sarcopenia in Head and Neck Computed Tomography: Cervical Muscle Mass as a Strong Indicator of Sarcopenia.","volume":"12","author":"F Ufuk","year":"2019","journal-title":"Clin Exp Otorhinolaryngol"},{"key":"pone.0294147.ref022","article-title":"Skeletal muscle mass and sarcopenia can be determined with 1.5-T and 3-T neck MRI scans, in the event that no neck CT scan is performed.","author":"AT Zwart","year":"2020","journal-title":"Eur Radiol."},{"issue":"4","key":"pone.0294147.ref023","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00405-019-05307-w","article-title":"Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra.","volume":"276","author":"SI Bril","year":"2019","journal-title":"Eur Arch Oto-Rhino-Laryngology"},{"issue":"6","key":"pone.0294147.ref024","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","article-title":"Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image","volume":"97","author":"W Shen","year":"2004","journal-title":"J Appl Physiol"},{"issue":"7","key":"pone.0294147.ref025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"CMM Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"pone.0294147.ref026","article-title":"The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study","author":"N Chargi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"14","key":"pone.0294147.ref027","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1200\/JCO.2004.12.012","article-title":"Preliminary results of Radiation Therapy Oncology Group 97\u201303: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.","volume":"22","author":"AS Garden","year":"2004","journal-title":"J Clin Oncol."},{"issue":"11","key":"pone.0294147.ref028","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial","volume":"36","author":"V Noronha","year":"2018","journal-title":"J Clin Oncol"},{"key":"pone.0294147.ref029","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1748-717X-7-215","article-title":"The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity","volume":"7","author":"D-L Tsan","year":"2012","journal-title":"Radiat Oncol"},{"issue":"3","key":"pone.0294147.ref030","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2010.06.038","article-title":"Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382).","volume":"81","author":"H Quon","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"pone.0294147.ref031","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/02841860701846160","article-title":"Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK.","volume":"47","author":"KF Ho","year":"2008","journal-title":"Acta Oncol (Madr)."},{"key":"pone.0294147.ref032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-3284-1-17","article-title":"Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.","volume":"1","author":"T Gupta","year":"2009","journal-title":"Head Neck Oncol"},{"issue":"3","key":"pone.0294147.ref033","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1743-7563.2011.01405.x","article-title":"Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients","volume":"7","author":"Z Otty","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"key":"pone.0294147.ref034","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1146\/annurev.nutr.17.1.527","article-title":"Human body composition: advances in models and methods","volume":"17","author":"SB Heymsfield","year":"1997","journal-title":"Annu Rev Nutr"},{"key":"pone.0294147.ref035","doi-asserted-by":"crossref","first-page":"104341","DOI":"10.1016\/j.oraloncology.2019.06.022","article-title":"Agreement between skeletal muscle mass measurements using computed tomography imaging and magnetic resonance imaging in head and neck cancer patients","volume":"99","author":"N Chargi","year":"2019","journal-title":"Oral Oncol"},{"issue":"5","key":"pone.0294147.ref036","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00405-019-05361-4","article-title":"Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer","volume":"276","author":"N Chargi","year":"2019","journal-title":"Eur Arch Oto-Rhino-Laryngology"},{"key":"pone.0294147.ref037","article-title":"Richtlijn Hoofd-halstumoren, chemoradiatie en bioradiatie van hoofd-hals [Internet].","author":"Federatie Medische Specialisten","year":"2014","journal-title":"Richtlijnendatabase"},{"key":"pone.0294147.ref038","author":"J Brierley","year":"2017","journal-title":"TNM Classification of Malignant Tumours"},{"issue":"9","key":"pone.0294147.ref039","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1634\/theoncologist.2017-0015","article-title":"Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.","volume":"22","author":"P Szturz","year":"2017","journal-title":"Oncologist"},{"issue":"5","key":"pone.0294147.ref040","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ijrobp.2012.05.008","article-title":"Long-term follow-up of the RTOG 9501\/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck","volume":"84","author":"JS Cooper","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"pone.0294147.ref041","first-page":"E2151","article-title":"Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.","volume":"38","author":"P Strojan","year":"2016","journal-title":"Head & neck."},{"key":"pone.0294147.ref042","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejca.2016.08.013","article-title":"Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma","volume":"67","author":"A Spreafico","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1079","key":"pone.0294147.ref043","doi-asserted-by":"crossref","first-page":"20170442","DOI":"10.1259\/bjr.20170442","article-title":"The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis.","volume":"90","author":"JK Jacinto","year":"2017","journal-title":"Br J Radiol."},{"issue":"11","key":"pone.0294147.ref044","article-title":"The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis.","volume":"9","author":"LFJ Huiskamp","year":"2020","journal-title":"J Clin Med."},{"issue":"10","key":"pone.0294147.ref045","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1016\/j.clnu.2021.08.023","article-title":"Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis.","volume":"40","author":"A Surov","year":"2021","journal-title":"Clin Nutr.Oct"},{"issue":"7","key":"pone.0294147.ref046","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1007\/s00405-021-07229-y","article-title":"Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer","volume":"279","author":"N Chargi","year":"2022","journal-title":"Eur Arch Oto-Rhino-Laryngology"},{"issue":"1","key":"pone.0294147.ref047","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.clnu.2020.05.020","article-title":"Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study.","volume":"40","author":"X Huang","year":"2021","journal-title":"Clin NutrJan"},{"issue":"6","key":"pone.0294147.ref048","first-page":"2001","article-title":"Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy","volume":"278","author":"R Shodo","year":"2021","journal-title":"Eur Arch oto-rhino-laryngology Off J Eur Fed Oto-Rhino-Laryngological Soc Affil with Ger Soc Oto-Rhino-Laryngology\u2014Head Neck Surg"},{"issue":"12","key":"pone.0294147.ref049","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.","volume":"31","author":"L Martin","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"16","key":"pone.0294147.ref050","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11164650","article-title":"Sex-Specific Cut-Off Values for Low Skeletal Muscle Mass to Identify Patients at Risk for Treatment-Related Adverse Events in Head and Neck Cancer.","volume":"11","author":"AT Zwart","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"pone.0294147.ref051","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.21037\/qims-21-911","article-title":"Cut-off values for low skeletal muscle mass at the level of the third cervical vertebra (C3) in patients with head and neck cancer.","volume":"12","author":"N Chargi","year":"2022","journal-title":"Quant Imaging Med Surg"},{"issue":"5","key":"pone.0294147.ref052","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jcsm.12443","article-title":"CT-measured skeletal muscle mass used to assess frailty in patients with head and neck cancer.","volume":"10","author":"AT Zwart","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"pone.0294147.ref053","doi-asserted-by":"crossref","first-page":"105558","DOI":"10.1016\/j.oraloncology.2021.105558","article-title":"Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer.","volume":"122","author":"SI Bril","year":"2021","journal-title":"Oral oncology. England"},{"key":"pone.0294147.ref054","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.oraloncology.2019.06.009","article-title":"Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer","volume":"95","author":"AR Jung","year":"2019","journal-title":"Oral Oncol"},{"issue":"3","key":"pone.0294147.ref055","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/odi.14074","article-title":"Evaluating the prognosis of oral squamous cell carcinoma patients via L3 skeletal muscle index","volume":"29","author":"X Lu","year":"2023","journal-title":"Oral Dis"},{"issue":"2","key":"pone.0294147.ref056","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MOO.0000000000000792","article-title":"Sarcopenia and its impact in head and neck cancer treatment.","volume":"30","author":"R de Bree","year":"2022","journal-title":"Curr Opin Otolaryngol Head Neck Surg"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T19:15:00Z","timestamp":1701112500000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294147"}},"subtitle":[],"editor":[{"given":"Antonino","family":"Maniaci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294147","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]}}}